Producer
Intas Pharmaceuticals
Indian generics maker; its Accord/Intas units made roughly half of US cisplatin/carboplatin until a 2023 FDA inspection halt triggered a national shortage.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Intas Pharmaceuticals supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Intas Pharmaceuticals makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Generic Injectables / Oncology
Global Generics (Accord Healthcare)
Branded / Biosimilars (India & EM)
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Incident2023
In 2023 cancer patients across the United States faced rationed chemotherapy because of a quality problem at a single factory in India. Intas Pharmaceuticals, through its Accord arm, supplied roughly half of America's cisplatin and carboplatin — cheap, decades-old generic chemo drugs that are first-line treatment for many cancers. Late in 2022 an FDA inspection of Intas's plant in Gujarat found serious manufacturing and data-integrity failures, and the company halted production. Because so much US supply funneled through that one facility, the country plunged into a severe shortage of these life-saving drugs, forcing oncologists to delay treatments, cut doses and choose which patients got the medicine. It was one of the starkest illustrations imaginable of single-source fragility: a routine regulatory inspection of one plant in one Indian state directly determined whether American cancer patients could get standard chemotherapy. The episode became a defining case in the debate over the resilience of the generic-drug supply chain.
Intas Pharmaceuticals Ltd. ↗Concentration2024
The cisplatin shortage exposed a perverse economics at the heart of essential medicine: the cheaper and more important a generic drug is, the more fragile its supply tends to be. Cisplatin and carboplatin are off-patent and sell for just a few dollars a vial, so margins are razor-thin and few manufacturers bother to make them — which concentrated US supply into a small number of low-cost producers, with Intas the dominant one. That is exactly backwards from how a critical-supply market should behave: the drugs society can least afford to lose are the ones almost nobody finds it worth producing, leaving them one inspection or one plant problem away from disappearing. The same dynamic recurs across sterile injectables (as with Hikma, Pfizer/Hospira and Teva): low price plus complex manufacturing plus thin competition equals chronic shortage risk for some of the most medically essential products in existence.
Intas Pharmaceuticals Ltd. ↗Origin2024
Intas is a reminder of how central India has become to the world's medicine cabinet, and how concentrated that role is in a few firms. A large, privately held company based in Ahmedabad, Gujarat, Intas built a global generics business — branded and generic in India and emerging markets, and a major US/European presence through its Accord Healthcare subsidiary — making it one of India's biggest pharmaceutical companies. India is often called "the pharmacy of the world" for its dominance in low-cost generics, but that dominance means a handful of Indian manufacturers and their specific plants sit in the critical path of drug supply for wealthy countries. Intas's cisplatin episode showed the flip side of that achievement: the same scale and cost efficiency that made affordable generics ubiquitous also concentrated risk, so that the regulatory and operational health of a few Indian factories now materially affects whether patients on the other side of the world can be treated.
Intas Pharmaceuticals Ltd. ↗